 |
 |
 |
 |
 |
 |
 |
|
 |
 |
Press ReleasesGenstruct's Award Winning Research Published, and to be Publicly PresentedBoston and Cambridge, Mass. — March 23, 2009 — ( IBC Life Sciences’ Targeting Metabolic Disorders Conference) - Genstruct Inc., a systems biology company focused on identifying molecular mechanisms, networks and biomarkers to better develop novel therapeutics, molecular diagnostics and patient-specific therapies, today announced that the results of its award-winning collaboration will be presented at the IBC Life Sciences’ Targeting Metabolic Disorders conference in Boston, and have been published in BioMed Central Systems Biology. Genstruct and collaborators elucidated the molecular mechanisms of action (MOA) for resveratrol, as well as another synthetic compound that specifically activates SIRT1, which is a member of the sirtuin family of enzymes that has been hypothesized to regulate the aging process. Resveratrol is the compound found in red wine that has been suggested to be responsible for the beneficial effects of red wine consumption. This collaboration was the winner of the Bio-IT World magazine’s 2008 Best Practices Award in drug discovery and development, and this presentation at IBC Life Sciences’ Targeting Metabolic Disorders Conference March 24 will highlight the results of the collaboration. A presentation titled "Small Molecule Activators of SIRT1 Replicate Signaling Pathways Triggered by Calorie Restriction in Mice", along with a poster by Renée Deehan Kenney, Ph.D., director of Scientific Research at Genstruct, titled “Causal Network Modeling of Small Molecule Activators of SIRT1 Replicate Signaling Pathways Triggered by Calorie Restriction In Vivo” will be presented. Additionally, a peer-reviewed scientific article describing the results of the project was published in the March 10th issue of BioMed Central Systems Biology. The article “Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo” was authored by a team of scientists co-led by Dr. Kenney. “We are excited to present the results of this pioneering project in metabolic disease research which was recognized as a Best Practice in Drug Discovery and Development by Bio-IT World magazine,” said Dr. Kenney. “SIRT1 activation has been implicated in improving longevity and determining the molecular mechanisms of natural and synthetic compounds that activate this enzyme may lead to new therapies to improve human health. We believe that by modeling the molecular mechanisms induced by activation of SIRT1, we can identify the molecular pathways responsible for diseases of aging.” Genstruct has further characterized the molecular MOA of SIRT1 activating compounds. In blinded analysis, Genstruct’s causal network modeling (CNM) approach concluded that the strongest hypothesis for the results seen in the Type 2 diabetes study was calorie restriction (CR) – showing that SIRT1 activators are mimicking the effects of CR. These results have been confirmed by in vitro and in vivo experiments. About Genstruct Founded in 2002, Genstruct is a systems biology company focused on elucidating the complexity of biology for the development of safe and effective therapeutics and molecular diagnostics. By developing Causal Network™ models for complex biological systems, Genstruct develops a deep molecular understanding of diseases and drug action, and designs mechanistic biomarkers and molecular diagnostics to facilitate drug development and personalized medicine. Genstruct’s Consulting Services division engages in short-, mid- and long-term partnerships with top tier pharmaceutical and life sciences companies, to develop new therapeutics and mechanistic biomarkers in the areas of oncology, metabolic disorders, cardiovascular diseases and inflammation. Genstruct was awarded the Bio-IT World 2008 Best Practices Award in the Drug Discovery & Development category for its joint collaboration with Sirtris Pharmaceuticals (a GSK company). Genstruct is a privately held company based in Cambridge, Mass. For more information, please visit www.genstruct.com. Contact: Karen Higgins A & E Communications for Genstruct (610) 831-5723 khiggins@aandecomm.com Return to Press Releases |
 |
|
 |
| One Alewife Center | Cambridge, MA 02140 | (617) 547-5421 | sitemap |